The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.
Michela SicaFederica BaroneCaterina NannelliPatrizia RicciLuana MaranoMaria De AngiolettiEros Di BonaAntonio Maria RisitanoRosario NotaroPublished in: British journal of haematology (2023)